Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States.

The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.

Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.

It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations.

The company was incorporated in 2016 and is headquartered in Montreal, Canada.